Stock Track | AbCellera Biologics Soars 7.62% After-Hours on Earnings Beat and Positive Clinical Data

Stock Track05-12

AbCellera Biologics' stock surged 7.62% in the after-hours session following the release of its first-quarter 2026 financial results and an update on its clinical pipeline.

The biotechnology company reported a narrower-than-expected quarterly loss and revenue that significantly exceeded analyst forecasts. AbCellera posted a loss of $0.14 per share, beating the FactSet consensus estimate for a loss of $0.17 per share. Revenue for the quarter reached $8.3 million, more than doubling from the year-ago period and surpassing the $5.9 million analyst estimate.

Investors also reacted positively to interim Phase 1 clinical data for the company's drug candidate ABCL635. The data showed a favorable tolerability profile with no serious adverse events, a pharmacokinetic profile supporting once-monthly dosing, and strong evidence of target engagement. The company ended the quarter with approximately $655 million in total available liquidity to fund its development strategy.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1124577415?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-12 04:45","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1124577415","market":"sg","top_or_hot":-1,"title":"Stock Track | AbCellera Biologics Soars 7.62% After-Hours on Earnings Beat and Positive Clinical Data","media":"Stock Track","content":"<p>AbCellera Biologics' stock surged 7.62% in the after-hours session following the release of its first-quarter 2026 financial results and an update on its clinical pipeline.</p><p>The biotechnology company reported a narrower-than-expected quarterly loss and revenue that significantly exceeded analyst forecasts. AbCellera posted a loss of $0.14 per share, beating the FactSet consensus estimate for a loss of $0.17 per share. Revenue for the quarter reached $8.3 million, more than doubling from the year-ago period and surpassing the $5.9 million analyst estimate.</p><p>Investors also reacted positively to interim Phase 1 clinical data for the company's drug candidate ABCL635. The data showed a favorable tolerability profile with no serious adverse events, a pharmacokinetic profile supporting once-monthly dosing, and strong evidence of target engagement. The company ended the quarter with approximately $655 million in total available liquidity to fund its development strategy.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | AbCellera Biologics Soars 7.62% After-Hours on Earnings Beat and Positive Clinical Data</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | AbCellera Biologics Soars 7.62% After-Hours on Earnings Beat and Positive Clinical Data\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-05-12 04:45</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>AbCellera Biologics' stock surged 7.62% in the after-hours session following the release of its first-quarter 2026 financial results and an update on its clinical pipeline.</p><p>The biotechnology company reported a narrower-than-expected quarterly loss and revenue that significantly exceeded analyst forecasts. AbCellera posted a loss of $0.14 per share, beating the FactSet consensus estimate for a loss of $0.17 per share. Revenue for the quarter reached $8.3 million, more than doubling from the year-ago period and surpassing the $5.9 million analyst estimate.</p><p>Investors also reacted positively to interim Phase 1 clinical data for the company's drug candidate ABCL635. The data showed a favorable tolerability profile with no serious adverse events, a pharmacokinetic profile supporting once-monthly dosing, and strong evidence of target engagement. The company ended the quarter with approximately $655 million in total available liquidity to fund its development strategy.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ABCL","symbol_name":"AbCellera Biologics","start_time":0,"source_url":"","article_id":"1124577415","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1124577415","pubTimestamp":1778532311,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"AbCellera Biologics' stock surged 7.62% in the after-hours session following the release of its first-quarter 2026 financial results and an update on its clinical pipeline.The biotechnology company...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ABCL":"AbCellera Biologics"},"translate_title":"个股追踪|AbCellera Biologics盘后飙升7.62%，因盈利超预期和积极的临床数据","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ABCL":1},"content_text":"AbCellera Biologics' stock surged 7.62% in the after-hours session following the release of its first-quarter 2026 financial results and an update on its clinical pipeline.The biotechnology company reported a narrower-than-expected quarterly loss and revenue that significantly exceeded analyst forecasts. AbCellera posted a loss of $0.14 per share, beating the FactSet consensus estimate for a loss of $0.17 per share. Revenue for the quarter reached $8.3 million, more than doubling from the year-ago period and surpassing the $5.9 million analyst estimate.Investors also reacted positively to interim Phase 1 clinical data for the company's drug candidate ABCL635. The data showed a favorable tolerability profile with no serious adverse events, a pharmacokinetic profile supporting once-monthly dosing, and strong evidence of target engagement. The company ended the quarter with approximately $655 million in total available liquidity to fund its development strategy.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1124577415","isCrawlerRequest":true}